Project: Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment
| Acronym | ImmuneNOVA (Reference Number: 11889) |
| Duration | 01/04/2018 |
| Project Topic | ImmuneNOVA aims to establish preclinical proof-of-concept in in vivo oncology models and in relevant patient-derived in vitro cell models for a novel immune checkpoint inhibitor targeting CMTM6. This inhibitor blocks a known immune checkpoint axis, PD-1/PD-L1, by decreasing cell surface expression of PD-L1, and so potentiates anti-tumour immunity. This novel inhibitor can be used to treat advanced forms of cancer, such as lung cancer, skin cancer (melanoma) and kidney cancer. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 8 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Scenic Biotech B.V. | Coordinator | Netherlands |
| 2 | Adlego Biomedical AB | Partner | Sweden |
| 3 | Ciloa SAS | Partner | France |
| 4 | InSphero AG | Partner | Switzerland |